Multicenter interlaboratory study of routine systems for the susceptibility testing of temocillin using a challenge panel of multidrug-resistant strains.

Antimicrobial susceptibility testing EUCAST Breakpoints Enterobacterales Temocillin

Journal

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology
ISSN: 1435-4373
Titre abrégé: Eur J Clin Microbiol Infect Dis
Pays: Germany
ID NLM: 8804297

Informations de publication

Date de publication:
Dec 2023
Historique:
received: 14 07 2023
accepted: 09 10 2023
pubmed: 23 10 2023
medline: 23 10 2023
entrez: 23 10 2023
Statut: ppublish

Résumé

Accurate susceptibility result of temocillin (TMO) is important for treating infections caused by multidrug-resistant Enterobacterales. This multicenter study aimed to investigate the performance of routine temocillin testing assays against Enterobacterales challenging strains. Forty-seven selected clinical isolates were blindly analyzed by 12 Belgian laboratories using VITEK® 2 (n = 5) and BD Phoenix™ (n = 3) automated systems, ETEST® gradient strip (n = 3), and disk (3 brands) diffusion method (DD; n = 6) for temocillin susceptibility using standardized methodology. Results were interpreted using EUCAST 2023 criteria and compared to the broth microdilution (BMD; Sensititre™ panel) method used as gold standard. Methods' reproducibility was assessed by testing 3 reference strains in triplicate. A total of 702 organism-drug results were obtained against 33 TMO-susceptible and 14 TMO-resistant isolates. Excluding Proteae species (P. mirabilis and M. morganii), the essential agreement rates were excellent (91.5-100%) for all MIC-based methods. The highest category agreement was achieved by ETEST® (97.5%) followed by VITEK® 2 (93.2%), disk diffusion (91.6%), and BD Phoenix™ (88.5%). BD Phoenix™ and paper disk diffusion overcalled resistance (11.5% and 6.8% of major discrepancies, respectively), while ROSCO tablets diffusion and VITEK® 2 generated higher very major discrepancies (7.1% and 4.2% respectively). Inter-assay reproducibility was unsatisfactory using recommended E. coli ATCC 25922 strain but was excellent with E. coli ATCC 35218 and K. pneumoniae ATCC 700603 strains. This interlaboratory study suggests that routine testing methods provide accurate and reproducible TMO categorization results except for Proteae species.

Identifiants

pubmed: 37870713
doi: 10.1007/s10096-023-04681-y
pii: 10.1007/s10096-023-04681-y
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1477-1483

Investigateurs

Jerina Boelens (J)
Laetitia Brassinne (L)
Lucy Catteau (L)
Pieter-Jan Ceyssens (PJ)
Julie Descy (J)
Stefanie Desmet (S)
Sarah Gils (S)
Katrien Latour (K)
Bénédicte Lissoir (B)
Koen Magerman (K)
Veerle Matheeussen (V)
Cécile Meex (C)
Hector Rodriguez Villalobos (H)
Sarah Vandamme (S)
Anne-Marie Van den Abeele (AM)
Aline Vilain (A)
Kris Vernelen (K)
Ingrid Wybo (I)
Harun Yaras (H)
Nicolas Yin (N)

Informations de copyright

© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Fuchs PC et al (1985) Interpretive criteria for temocillin disk diffusion susceptibility testing. Eur J Clin Microbiol 4(1):30–33
doi: 10.1007/BF02148656 pubmed: 3872793
Alexandre K et al (2021) Efficacy of temocillin against MDR Enterobacterales: a retrospective cohort study. J Antimicrob Chemother 76(3):784–788
doi: 10.1093/jac/dkaa486 pubmed: 33254232
Giske CG et al (2021) Comment on: Efficacy of temocillin against MDR Enterobacterales: a retrospective cohort study. J Antimicrob Chemother 76(7):1949–1950
doi: 10.1093/jac/dkab081 pubmed: 33724352
Alexandre K, Caron F (2021) Efficacy of temocillin against MDR Enterobacterales: a retrospective cohort study-authors’ response. J Antimicrob Chemother 76(7):1950–1951
doi: 10.1093/jac/dkab129 pubmed: 33893503
Heard KL et al (2021) Clinical outcomes of temocillin use for invasive Enterobacterales infections: a single-centre retrospective analysis. JAC Antimicrob Resist 3(1):dlab005
doi: 10.1093/jacamr/dlab005 pubmed: 34223083 pmcid: 8210019
Deckers C et al (2022) Multicentre interlaboratory analysis of routine susceptibility testing with a challenge panel of resistant strains. J Glob Antimicrob Resist 28:125–129
doi: 10.1016/j.jgar.2021.12.020 pubmed: 35026463
The European committee on antimicrobial susceptibility testing, routine and extended internal quality control for MIC determination and disk diffusion as recommended by EUCAST. Version 13.1, (2023). Available from: http://www.eucast.org
Maurissen W et al (2015) Establishing quality control ranges for temocillin following CLSI-M23-A3 guideline. Acta Clin Belg 70(1):11–15
doi: 10.1179/2295333714Y.0000000066 pubmed: 25176405
The European committee on antimicrobial susceptibility testing, breakpoint tables for interpretation of MICs and zone diameters. Version 13.0, (2023). Available from: http://www.eucast.org
Oosterbos J et al (2022) Clinical and microbiological evaluation of temocillin for bloodstream infections with Enterobacterales: a Belgian single-centre retrospective study. JAC Antimicrob Resist 4(4):dlac086
doi: 10.1093/jacamr/dlac086 pubmed: 36003075 pmcid: 9397121
Vanstone GL et al (2013) Temocillin disc diffusion susceptibility testing by EUCAST methodology. J Antimicrob Chemother 68(11):2688–2689
doi: 10.1093/jac/dkt248 pubmed: 23828022
Mertens K (2021) European antimicrobial resistance surveillance network - Belgium (EARS-NET) report 2021. Sciensano. Available from: https://www.sciensano.be/en/projects/european-antimicrobial-resistance-surveillance-belgium
Alexandre K et al (2018) Temocillin against Enterobacteriaceae isolates from community-acquired urinary tract infections: low rate of resistance and good accuracy of routine susceptibility testing methods. J Antimicrob Chemother 73(7):1848–1853
doi: 10.1093/jac/dky101 pubmed: 29635629
Simon A, Camps K, De Beenhouwer H, Glibert B, Meunier F, Trouve A, Vael V, Tulkens PM, Carryn S (2007) Phoenix is overcalling the resistance of Enterobacteriaceae to Temocillin, in Abstract of the 47th ICAAC. Available from: https://www.facm.ucl.ac.be/posters/2007/ICAAC/ICAAC-2007-D24-Simon-et-al.pdf
Patel TA, Dilley R, Williams A, Vanstone GL, Balakrishnan I (2013) Comparison of the Phoenix automated system, the ETEST method and broth microdilution in determining temocillin susceptibility of Enterobacteriaceae. J Antimicrob Chemother 68(7):1685–1686
doi: 10.1093/jac/dkt049 pubmed: 23416956
Luzzaro F, Lombardi G, Perilli M, Belloni R, Amicosante G, Toniolo A (2001) Antimicrobial susceptibility testing and ESBL production in clinical isolates of Proteus mirabilis: an evaluation with the Phoenix™ automated microbiology system, in 101st general meeting of the American society for microbiology, Orlando, Florida. Available from : https://www.researchgate.net/publication/237236027_Antimicrobial_Susceptibility_Testing_and_ESBL_Production_in_Clinical_Isolates_of_Proteus_Mirabilis_An_Evaluation_with_the_Phoenix_Automated_Microbiology_System
Société Française de Microbiologie, in CA-SFM/EUCAST: Société Française de Microbiologie (ed) (2023) 49–50. Available from : https://www.sfm-microbiologie.org/wp-content/uploads/2023/06/CASFM2023_V1.0.pdf
Van den Broucke E, Thijs L, Desmet S, Vander Elst L, Gijsen M, Mylemans M, Van de Gaer O, Peetermans WE, Quintens C, Spriet I (2022) Clinical efficacy of temocillin standard dosing in patients treated with outpatient antimicrobial therapy. Pharmaceutics.  https://doi.org/10.3390/pharmaceutics14112289

Auteurs

Corentin Deckers (C)

Laboratory of Clinical Microbiology, CHU UCL Namur, UCLouvain, Site Godinne, Avenue Gaston Therasse, 1, 5530, Yvoir, Belgium. corentin.deckers@uclouvain.be.

Florian Bélik (F)

Laboratory of Clinical Microbiology, CHU UCL Namur, UCLouvain, Site Godinne, Avenue Gaston Therasse, 1, 5530, Yvoir, Belgium.

Olivier Denis (O)

Laboratory of Clinical Microbiology, CHU UCL Namur, UCLouvain, Site Godinne, Avenue Gaston Therasse, 1, 5530, Yvoir, Belgium.

Isabel Montesinos (I)

Laboratory of Clinical Microbiology, CHU UCL Namur, UCLouvain, Site Godinne, Avenue Gaston Therasse, 1, 5530, Yvoir, Belgium.

Pierre Bogaerts (P)

Laboratory of Clinical Microbiology, CHU UCL Namur, UCLouvain, Site Godinne, Avenue Gaston Therasse, 1, 5530, Yvoir, Belgium.

Jerina Boelens (J)

Laboratory of Clinical Microbiology, UZ Gent, Ghent, Belgium.

Laetitia Brassinne (L)

Laboratory of Clinical Microbiology, Cliniques de L'Europe, Brussels, Belgium.

Julie Descy (J)

Laboratory of Clinical Microbiology, Clinique André Renard, Herstal, Belgium.

Stefanie Desmet (S)

Laboratory of Clinical Microbiology, UZ Leuven, Louvain, Belgium.

Sarah Gils (S)

Laboratory of Clinical Microbiology, Medisch Centrum Huisartsen, Louvain, Belgium.

Bénédicte Lissoir (B)

Laboratory of Clinical Microbiology, Grand Hôpital de Charleroi, Charleroi, Belgium.

Koen Magerman (K)

Laboratory of Clinical Microbiology, Jessa Ziekenhuis, Hasselt, Belgium.

Veerle Matheeussen (V)

Laboratory of Clinical Microbiology, UZ Antwerp, Antwerp, Belgium.

Cécile Meex (C)

Laboratory of Clinical Microbiology, CHU de Liège, Liège, Belgium.

Hector Rodriguez Villalobos (H)

Laboratory of Clinical Microbiology, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium.

Anne Marie Van den Abeele (AM)

Laboratory of Clinical Microbiology, AZ Sint-Lucas, Ghent, Belgium.

Kris Vernelen (K)

Quality of Laboratories, Sciensano, Brussels, Belgium.

Pieter-Jan Ceyssens (PJ)

Unit of Human Bacterial Diseases, Sciensano, Brussels, Belgium.

Te-Din Huang (TD)

Laboratory of Clinical Microbiology, CHU UCL Namur, UCLouvain, Site Godinne, Avenue Gaston Therasse, 1, 5530, Yvoir, Belgium.

Classifications MeSH